Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 2700+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 30 - May 3, 2026

May 4, 2026

•

3 min read

Biotech & Pharma Updates | April 30 - May 3, 2026

🧬 Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations, UCB to acquire Candid Therapeutics for $2.2B, expanding T-cell engager pipeline for autoimmune diseases, FDA names Katherine Szarama as acting CBER director following Vinay Prasad's departure

Christian Cuchapin, +1

Long Form Content

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

May 2, 2026

•

15 min read

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

Why securitization might be the way towards greater CGT and advanced therapy access

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 29 - 30,

May 1, 2026

•

4 min read

Biotech & Pharma Updates | April 29 - 30,

🧬 Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia, AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones, UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%

Christian Cuchapin, +1

Biotech & Pharma Updates | April 28 - 29, 2026

Apr 30, 2026

•

3 min read

Biotech & Pharma Updates | April 28 - 29, 2026

🧬 GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts, Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly, Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases

Christian Cuchapin, +1

Biotech & Pharma Updates | April 27 - 28, 2026

Apr 29, 2026

•

4 min read

Biotech & Pharma Updates | April 27 - 28, 2026

🧬 AbbVie gains exclusive right to acquire Kestrel Therapeutics for up to $1.45B - targeting oral pan-KRAS inhibitor, Coultreon Biopharma raises $125M Series A to advance oral SIK3 autoimmune drug, Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180M, Eli Lilly + Profluent Bio partner on AI-designed DNA editing tools for genetic medicines - up to $2.25B milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 26 - 27

Apr 28, 2026

•

4 min read

Biotech & Pharma Updates | April 26 - 27

🧬 Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging + chronic diseases, Intellia Therapeutics' lonvo-z succeeds in Ph3 trial for hereditary angioedema - company begins rolling FDA submission, Thermo Fisher Scientific divests microbiology business to Astorg for $1.075B, UK biotech VC funding rises 17% in Q1 2026 - showing recovery signs but IPO activity remains stagnant

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 23 - 26, 2026

Apr 27, 2026

•

3 min read

Biotech & Pharma Updates | April 23 - 26, 2026

🧬 Sun Pharma to acquire Organon for $12.5B in largest-ever overseas deal by Indian company, FDA awards national priority vouchers to Compass Pathways + Transcend Therapeutics + Usona Institute for psychedelic treatments, Johnson & Johnson launches 4 prescription drugs on Trump administration's TrumpRx discounted pharmaceutical website, EMA recommends approval of Sanofi's tolebrutinib for secondary progressive multiple sclerosis after FDA rejection

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 22 - 23, 2026

Apr 24, 2026

•

3 min read

Biotech & Pharma Updates | April 22 - 23, 2026

🧬 Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs, Regeneron Pharmaceuticals' Otarmeni wins FDA approval for otoferlin-deficient congenital hearing loss following Ph1/2 success, Evonik invests €80M ($93.6M) in Slovakia facility to boost fermentation capabilities - adding 50 jobs, Novo Nordisk's Rybelsus (semaglutide) meets Ph3 goals in pediatric type 2 diabetes + supporting label expansion filings

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 21 - 22, 2026

Apr 23, 2026

•

3 min read

Biotech & Pharma Updates | April 21 - 22, 2026

🧬 Merck & Co. + Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B, AbbVie invests $1.4B to build 185-acre Durham NC production hub - creating 730-plus jobs, Amneal acquires Kashiv BioSciences for $1.1B to expand biosimilars pipeline amid market growth, Moderna's mCOMBRIAX (mRNA-1010/mNEXSPIKE) wins European Commission approval for influenza and COVID-19 combination immunization in adults 50 and older

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 30 - May 3, 2026

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

Biotech & Pharma Updates | April 29 - 30,

Biotech & Pharma Updates | April 28 - 29, 2026

Biotech & Pharma Updates | April 27 - 28, 2026

Biotech & Pharma Updates | April 26 - 27

Biotech & Pharma Updates | April 23 - 26, 2026

Biotech & Pharma Updates | April 22 - 23, 2026

Biotech & Pharma Updates | April 21 - 22, 2026

TLDR Biotech

FAQ

Media Partners